Cargando…

Efficacy and safety of remimazolam for non-obese patients during anesthetic induction in cardiac surgery: study protocol for a multicenter randomized trial

BACKGROUND: Valvular heart disease remains common in both developed and developing countries, and it requires timely surgical treatment when necessary. However, the stability of hemodynamics during anesthesia induction in patients undergoing valve replacement surgery is difficult to maintain due to...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Hong, Liu, Hong-Mei, Li, Ping, Yu, Hai, Liu, Bin, Liang, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727858/
https://www.ncbi.nlm.nih.gov/pubmed/36476322
http://dx.doi.org/10.1186/s13063-022-06965-8
_version_ 1784845116373991424
author Yu, Hong
Liu, Hong-Mei
Li, Ping
Yu, Hai
Liu, Bin
Liang, Peng
author_facet Yu, Hong
Liu, Hong-Mei
Li, Ping
Yu, Hai
Liu, Bin
Liang, Peng
author_sort Yu, Hong
collection PubMed
description BACKGROUND: Valvular heart disease remains common in both developed and developing countries, and it requires timely surgical treatment when necessary. However, the stability of hemodynamics during anesthesia induction in patients undergoing valve replacement surgery is difficult to maintain due to their impaired cardiac function. Remimazolam, a novel and ultrashort-acting intravenous sedative-hypnotic, may be beneficial to stable hemodynamics, but the evidence is limited. Therefore, this study aims to evaluate the effect of remimazolam induction on hemodynamics compared with midazolam and etomidate in patients undergoing valve replacement surgery. METHODS: This is a prospective, multicenter randomized controlled trial (RCT). Three hundred and sixty-three non-obese adult patients aged 45 to 80 years old undergoing valve surgery with cardiopulmonary bypass will be randomly allocated to receive remimazolam tosilate, midazolam, or etomidate during anesthetic induction. The primary outcome is the incidence of hypotension within 20 min after the administration of investigated drugs. The hypotension is defined as systolic blood pressure (SBP) < 90 mmHg or a 30% reduction in SBP from baseline or the application of vasoactive drugs. Secondary outcomes include incidence of successful sedation, time to successful sedation, incidence of delirium and postoperative low cardiac output syndrome within 7 days after surgery, hospital mortality, mechanical ventilation time, ICU length of stay, and hospital length of stay. DISCUSSION: To our knowledge, this is the first prospective RCT to investigate the efficacy and safety of remimazolam induction in adult cardiac surgery compared with midazolam and etomidate. This study will provide important information on the application of remimazolam in cardiac surgery in the future. TRIAL REGISTRATION: Chinese Clinical Trial Registry chictr.org.cn ChiCTR2100050122. Registered on August 16, 2021. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06965-8.
format Online
Article
Text
id pubmed-9727858
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97278582022-12-08 Efficacy and safety of remimazolam for non-obese patients during anesthetic induction in cardiac surgery: study protocol for a multicenter randomized trial Yu, Hong Liu, Hong-Mei Li, Ping Yu, Hai Liu, Bin Liang, Peng Trials Study Protocol BACKGROUND: Valvular heart disease remains common in both developed and developing countries, and it requires timely surgical treatment when necessary. However, the stability of hemodynamics during anesthesia induction in patients undergoing valve replacement surgery is difficult to maintain due to their impaired cardiac function. Remimazolam, a novel and ultrashort-acting intravenous sedative-hypnotic, may be beneficial to stable hemodynamics, but the evidence is limited. Therefore, this study aims to evaluate the effect of remimazolam induction on hemodynamics compared with midazolam and etomidate in patients undergoing valve replacement surgery. METHODS: This is a prospective, multicenter randomized controlled trial (RCT). Three hundred and sixty-three non-obese adult patients aged 45 to 80 years old undergoing valve surgery with cardiopulmonary bypass will be randomly allocated to receive remimazolam tosilate, midazolam, or etomidate during anesthetic induction. The primary outcome is the incidence of hypotension within 20 min after the administration of investigated drugs. The hypotension is defined as systolic blood pressure (SBP) < 90 mmHg or a 30% reduction in SBP from baseline or the application of vasoactive drugs. Secondary outcomes include incidence of successful sedation, time to successful sedation, incidence of delirium and postoperative low cardiac output syndrome within 7 days after surgery, hospital mortality, mechanical ventilation time, ICU length of stay, and hospital length of stay. DISCUSSION: To our knowledge, this is the first prospective RCT to investigate the efficacy and safety of remimazolam induction in adult cardiac surgery compared with midazolam and etomidate. This study will provide important information on the application of remimazolam in cardiac surgery in the future. TRIAL REGISTRATION: Chinese Clinical Trial Registry chictr.org.cn ChiCTR2100050122. Registered on August 16, 2021. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06965-8. BioMed Central 2022-12-07 /pmc/articles/PMC9727858/ /pubmed/36476322 http://dx.doi.org/10.1186/s13063-022-06965-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Yu, Hong
Liu, Hong-Mei
Li, Ping
Yu, Hai
Liu, Bin
Liang, Peng
Efficacy and safety of remimazolam for non-obese patients during anesthetic induction in cardiac surgery: study protocol for a multicenter randomized trial
title Efficacy and safety of remimazolam for non-obese patients during anesthetic induction in cardiac surgery: study protocol for a multicenter randomized trial
title_full Efficacy and safety of remimazolam for non-obese patients during anesthetic induction in cardiac surgery: study protocol for a multicenter randomized trial
title_fullStr Efficacy and safety of remimazolam for non-obese patients during anesthetic induction in cardiac surgery: study protocol for a multicenter randomized trial
title_full_unstemmed Efficacy and safety of remimazolam for non-obese patients during anesthetic induction in cardiac surgery: study protocol for a multicenter randomized trial
title_short Efficacy and safety of remimazolam for non-obese patients during anesthetic induction in cardiac surgery: study protocol for a multicenter randomized trial
title_sort efficacy and safety of remimazolam for non-obese patients during anesthetic induction in cardiac surgery: study protocol for a multicenter randomized trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727858/
https://www.ncbi.nlm.nih.gov/pubmed/36476322
http://dx.doi.org/10.1186/s13063-022-06965-8
work_keys_str_mv AT yuhong efficacyandsafetyofremimazolamfornonobesepatientsduringanestheticinductionincardiacsurgerystudyprotocolforamulticenterrandomizedtrial
AT liuhongmei efficacyandsafetyofremimazolamfornonobesepatientsduringanestheticinductionincardiacsurgerystudyprotocolforamulticenterrandomizedtrial
AT liping efficacyandsafetyofremimazolamfornonobesepatientsduringanestheticinductionincardiacsurgerystudyprotocolforamulticenterrandomizedtrial
AT yuhai efficacyandsafetyofremimazolamfornonobesepatientsduringanestheticinductionincardiacsurgerystudyprotocolforamulticenterrandomizedtrial
AT liubin efficacyandsafetyofremimazolamfornonobesepatientsduringanestheticinductionincardiacsurgerystudyprotocolforamulticenterrandomizedtrial
AT liangpeng efficacyandsafetyofremimazolamfornonobesepatientsduringanestheticinductionincardiacsurgerystudyprotocolforamulticenterrandomizedtrial